Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by Temozolomide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Temozolomide (Temodar, Merck)  is an orally or parenterally available alkylating drug indicated for the treatment of adult patients with primary brain tumor. Initially approved by the Food and Drug Administration (FDA) in 1999 for refractory anaplastic astrocytoma, it was subsequently approved for the primary treatment of glioblastoma multiforme with concomitant radiotherapy in 2005 [1–3]. Temozolomide is also used off-label for selected patients with metastatic melanoma with encouraging results [4, 5]. The oral or intravenous daily dose of temozolomide is 75–200 mg/m2 for varying duration depending on the clinical setting. The main dose limiting side effects are related to myelosuppression, with only a minority of patients experiencing reversible neutropenia, thrombocytopenia, and anemia that leads to early cessation of the drug. The most commonly reported non-hematologic adverse events are nausea, vomiting, headache, fatigue, and constipation that develop in 10 % or mo
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. CrossRef
- Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762–2771.
- Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144–151. CrossRef
- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166.
- Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67:446–458. CrossRef
- Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287–291. CrossRef
- Mikkelsen T, Anderson J, Doyle TJ, et al. Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis. J Neurooncol. 2010;100:241–247.
- Web-Page. http://www.spfiles.com/pitemodar.pdf.
- Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934, 1934 e1921–e1924.
- Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68. CrossRef
- Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272–276. CrossRef
- Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5:309–317.
- Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010;31:1383–1384.
- Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009;64:647–655. CrossRef
- Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35–61. CrossRef
- Erichsen C, Jonsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol. 1984;27:268–270. CrossRef
- Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. Cancer Gene Ther. 2000;7:233–239. CrossRef
- Web Page. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
- Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126. CrossRef
- Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by Temozolomide
Digestive Diseases and Sciences
Volume 58, Issue 5 , pp 1415-1421
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Temozolomide toxicity
- Temozolomide hepatotoxicity
- Drug-induced liver injury
- Temozolomide hepatitis
- Industry Sectors
- Author Affiliations
- 1. Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8887, USA
- 2. National Cancer Institute, Bethesda, MD, USA
- 3. University of Michigan, Ann Arbor, MI, USA
- 4. Indiana University, Indianapolis, IN, USA